Table

· · · · · · · · · · · · · · · · · · ·	Episodes of CDI with recurrence (n=21)		Episodes of CDI without recurrence (n=154)		
	n/ median	%/range	n/ median	%/range	p-value
Demographics					
Male	16	76.2	88	57.1	0.104*
Age (years)	3.81	1-20	9.9	1-21	0.082^{+}
Age categories					
< 6 years	13	61.9	56	36.4	0.085^{*}
6-12 years	2	9.5	35	22.7	
>12 years	6	28.6	63	40.9	
Healthcare exposures					0.048
HO-HCFA CDI	6	28.6	82	53.3	
CO-HCFA CDI	4	19.1	33	21.4	
CA-CDI	8	38.1	24	15.6	
Indeterminate CDI	3	14.3	15	9.7	
Clinical features at diagnosis					
Fever	11	52.4	60	39.0	0.240
Hemodynamic instability	1	4.8	7	4.6	1.000^{*}
Signs of severe colitis in imaging	1	4.8	9	5.8	1.000*
Disease severity					
Severe CDI	4	19.1	53	34.4	0.216*
Comorbid conditions					
Cancer	4	19.0	30	19.5	1.000^{*}
Immunosuppression	11	52.4	65	42.2	0.378
Exposures/risk factors					
Antibiotic exposure ⁺⁺	18	85.7	107	69.5	0.196*
Antacids ⁺⁺	14	66.7	86	55.8	0.347
Prior chemotherapy ^{**}	5	23.8	34	22.1	0.787^{*}
History of CDI	4	19.1	15	9.7	0.253*
Treatment					
Duration of treatment (days)	10	7-19	10	2-54	0.378
Type of treatment					0.611
Metronidazole only	18	85.7	133	86.4	
Vancomycin only	3	14.3	12	7.8	
Metronidazole and vancomycin	0	0.0	6	3.9	
Rifaximin only	0	0.0	1	0.7	
Administration of metronidazole		107.7			0.600
Per oral	19	100.0	134	93.7	
Intravenous	0	0.0	9	6.3	
Receipt of other antibiotics during treatment of CDI	15	71.4	76	49.4	0.057

Table 1. Baseline characteristics and healthcare exposures for 175 children hospitalized with Clostridium difficile infection

CDI: C. difficile infection

HO-HCFA CDI: Healthcare facility-onset healthcare facility-associated CDI CO-HCFA CDI: Community-onset healthcare facility-associated CDI

CA-CDI: Community-associated CDI

CRP: C-reactive protein

Wilcoxon Mann-Whitney U Test

* Fisher's exact test

⁺⁺Within the last 30 days

**Within the last 6 months